Ep135: John Maraganore on Developing a New Class of Medicines episode artwork

EPISODE · May 8, 2023 · 1H 3M

Ep135: John Maraganore on Developing a New Class of Medicines

from The Long Run with Luke Timmerman · host Timmerman Report

John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.

John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.

NOW PLAYING

Ep135: John Maraganore on Developing a New Class of Medicines

0:00 1:03:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Long Run with Luke Timmerman?

This episode is 1 hour and 3 minutes long.

When was this The Long Run with Luke Timmerman episode published?

This episode was published on May 8, 2023.

What is this episode about?

John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.

Can I download this The Long Run with Luke Timmerman episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!